Table of Content

Abstract
Acknowledgements
Table of Content
List of Table
List of Figure
I. INTRODUCTION
1.1. Background
1.2. Aim of the Study
1.3. Research Motivation
II. LITERATURE REVIEW
2.1. Inflammatory bowel diseases (IBD)
2.1.1. Classification of IBD
2.1.2. Pathophysiology
2.2. DSS – Animal models of inflammatory bowel diseases
2.2.1. Dextran sulfate sodium (DSS
2.2.2. Advantage of DSS colitis mouse model
2.2.3. Colitis procedure
2.2.4. Dextran sulfate sodium colitis mouse model
2.2.5. The molecular weight of DSS
2.2.6. Clinical features
2.2.7. Pathological features of DSS colitis
2.2.8. Pathogenesis of DSS colitis
2.3. Bilirubin
2.3.1. Bilirubin: chemical structure and formation
2.3.2. Bilirubin metabolism
2.3.3. Toxicity of bilirubin
2.3.4. Bilirubin as an antioxidant
III. MATERIALS AND METHODS
3.1. Materials
3.1.1. Preparation of bilirubin
3.1.2. Preparation DSS solution
3.2. Experimental Design
3.3. Animals
3.4. Induction of colitis
3.5. Assessment of DSS colitis
3.6. Histopathological analysis
3.7. Statistical Analysis
IV. RESULTS AND DISCUSSIONS
4.1. The effects of DSS molecular weight to induce colitis in mice
4.2. Effects of bilirubin (BR) in the dextran sulphate sodium (DSS) mouse model – Induced experimental colitis
4.2.1. Oral administration of bilirubin prevents body weight loss in the DSS-induced colitis model
4.2.2. Assessment of disease activity index in mice
4.2.3. Bilirubin prevented the colonic shortening induced and prevented the reducing liver weight induced by DSS
4.2.4. Histologic findings in DSS-induced colitis
V. CONCLUSION
REFERENCE

APPENDIX